Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q1 2023 call → NOThe question asks whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is already visible. This requires three elements: (1) a proven instance that already works, (2) copies physically being stood up now, and (3) demand already identified at the destination. Let me review the transcript. The company is Trevi Therapeutics, developing Haduvio for chronic cough in IPF, refractory chronic cough, and prurigo nodularis. The key programs discussed: - IPF chronic cough: planning a Phase 2b dose-ranging trial and a Phase 1b respiratory physiology study. These are clinical trials, not yet initiated. The company is preparing protocols, engaging CROs, and planning to initiate in the second half of this year. - Refractory chronic cough (RCC): developing a protocol for a Phase 2 study, expected to enroll ~60 subjects. Not yet initiated. - Prurigo nodularis: completed the one-year open-label extension study, analyzing data, seeking end of Phase 2 meeting. - Human abuse potential study: Part 1 completed, Part 2 pending. The question is about copying a proven part of the business into additional places. The company is planning clinical trials in different indications (IPF cough, RCC). But these are clinical trials, not yet initiated. The company has prior data (CANAL trial in IPF, PRISM trial in PN), but the new trials are not yet stood up — they are planned, protocols being finalized, regulatory submissions pending. The trials are not yet initiated. The company says "We are planning on initiating this study in the second half of this year" for the IPF dose-ranging study, and "We expect to initiate this study in the second half of this year" for the Phase 1b. The RCC trial is "developing a protocol." So the copies (new trials) are not physically being stood up now — they are planned, in preparation, not yet initiated. The demand at destination — the company describes unmet medical need, but not demand already visible at the destination in the sense of committed patients or waiting lists. Also, the "proven instance" — the CANAL trial was a Phase 2a proof-of-concept, not a commercial operation. The company is a clinical-stage biotech, not operating a business with proven instances being replicated.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.